D.A. Davidson & CO. Makes New $1.16 Million Investment in Personalis, Inc. $PSNL

D.A. Davidson & CO. purchased a new position in shares of Personalis, Inc. (NASDAQ:PSNL) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 145,507 shares of the company’s stock, valued at approximately $1,158,000.

Other large investors have also recently bought and sold shares of the company. Legal & General Group Plc acquired a new position in Personalis during the 2nd quarter worth approximately $30,000. BNP Paribas Financial Markets raised its stake in shares of Personalis by 406.4% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock worth $42,000 after purchasing an additional 5,177 shares in the last quarter. Farther Finance Advisors LLC bought a new stake in shares of Personalis during the 3rd quarter worth approximately $66,000. FourThought Financial Partners LLC bought a new stake in shares of Personalis during the 3rd quarter worth approximately $86,000. Finally, Focus Partners Wealth bought a new stake in shares of Personalis during the 1st quarter worth approximately $47,000. Institutional investors and hedge funds own 61.91% of the company’s stock.

Personalis Price Performance

Shares of Personalis stock opened at $5.78 on Monday. Personalis, Inc. has a 12-month low of $3.84 and a 12-month high of $11.50. The stock has a market cap of $605.05 million, a P/E ratio of -6.35 and a beta of 1.96. The business’s 50 day moving average is $7.07 and its 200-day moving average is $8.30.

Personalis (NASDAQ:PSNL) last posted its quarterly earnings results on Thursday, February 26th. The company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.05. Personalis had a negative return on equity of 39.13% and a negative net margin of 116.69%.The business had revenue of $17.35 million for the quarter, compared to analysts’ expectations of $17.12 million. On average, sell-side analysts expect that Personalis, Inc. will post -1.01 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on PSNL shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Personalis in a research note on Tuesday, April 21st. Guggenheim upped their price objective on Personalis from $12.00 to $13.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. BTIG Research upped their price objective on Personalis from $12.00 to $13.00 and gave the stock a “buy” rating in a research note on Wednesday, February 11th. Wall Street Zen upgraded Personalis from a “sell” rating to a “hold” rating in a research note on Sunday, March 8th. Finally, Morgan Stanley dropped their price objective on Personalis from $11.00 to $10.00 and set an “equal weight” rating on the stock in a research note on Thursday, March 5th. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Personalis currently has a consensus rating of “Moderate Buy” and an average target price of $11.50.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.